Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III

Antonio Ceriello, Marco Sardina, Enrico Motz, Sebastiano Lizzio, Duilio Tuniz, Carlo Bianchini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Twenty patients, 15 males and 5 females, aged 50-71 years, with peripheral obstructive arterial disease at Fontaine stage III and requiring hospitalization, were randomized to two different iloprost treatment schedules: iloprost i.v. infusion, up to 2 ng/kg/minute for 6 hours/day for 28 days (Group A) or iloprost i.v. infusion, up to 1.5 ng/kg/minute, for 16 hours/day for 7 days (Group B). At baseline, after 7 days (end of treatment, Group B only) and after 28 days (end of study) the following measurements were done: blood pressure and heart rate, ankle/arm pressure index, first flow, peak flow, time to regression (by means of mercury strain-gauge plethysmography), stroke volume, cardiac output, ejection fraction (by means of 2D-echocardiography and echo-Doppler), exercise tolerance (by means of treadmill test), and rest pain (by means of visual analogue scale). Both treatment schedules resulted in significant improvement in plethysmographic parameters and exercise tolerance (both maximal and pain free) with concomitant reduction in rest pain. These effects were long lasting as evident by the results observed in Group: B where the absolute data after 3 weeks of drug withdrawal were superimposable to those of Group A. On the contrary, only mild effects were evident on systemic hemodynamics, which tended to wane off as the infusion was stopped. From the results of this pilot study it is possible to conclude that treatment with iloprost at lower dosage (up to 1.5 ng/kg/minute) for 16 hour/day for 7 days, in patients at Fontaine stage III, seems to result in the same therapeutic benefits of the currently used schedule (up to 2 ng/kg/minute for 6 hour/day for 28 days). If confirmed by larger clinical experience, these data have clear implication in terms of patient comfort and cost containment.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalInternational Journal of Angiology
Volume7
Issue number1
DOIs
Publication statusPublished - 1998

Fingerprint

Iloprost
Exercise Tolerance
Peripheral Arterial Disease
Hemodynamics
Appointments and Schedules
Therapeutics
Plethysmography
Cost Control
Doppler Echocardiography
Pain Measurement
Mercury
Exercise Test
Ankle
Cardiac Output
Stroke Volume
Hospitalization
Arm
Heart Rate
Blood Pressure
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{0f0e1c64762046ee9264fbc1feb533f2,
title = "Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III",
abstract = "Twenty patients, 15 males and 5 females, aged 50-71 years, with peripheral obstructive arterial disease at Fontaine stage III and requiring hospitalization, were randomized to two different iloprost treatment schedules: iloprost i.v. infusion, up to 2 ng/kg/minute for 6 hours/day for 28 days (Group A) or iloprost i.v. infusion, up to 1.5 ng/kg/minute, for 16 hours/day for 7 days (Group B). At baseline, after 7 days (end of treatment, Group B only) and after 28 days (end of study) the following measurements were done: blood pressure and heart rate, ankle/arm pressure index, first flow, peak flow, time to regression (by means of mercury strain-gauge plethysmography), stroke volume, cardiac output, ejection fraction (by means of 2D-echocardiography and echo-Doppler), exercise tolerance (by means of treadmill test), and rest pain (by means of visual analogue scale). Both treatment schedules resulted in significant improvement in plethysmographic parameters and exercise tolerance (both maximal and pain free) with concomitant reduction in rest pain. These effects were long lasting as evident by the results observed in Group: B where the absolute data after 3 weeks of drug withdrawal were superimposable to those of Group A. On the contrary, only mild effects were evident on systemic hemodynamics, which tended to wane off as the infusion was stopped. From the results of this pilot study it is possible to conclude that treatment with iloprost at lower dosage (up to 1.5 ng/kg/minute) for 16 hour/day for 7 days, in patients at Fontaine stage III, seems to result in the same therapeutic benefits of the currently used schedule (up to 2 ng/kg/minute for 6 hour/day for 28 days). If confirmed by larger clinical experience, these data have clear implication in terms of patient comfort and cost containment.",
author = "Antonio Ceriello and Marco Sardina and Enrico Motz and Sebastiano Lizzio and Duilio Tuniz and Carlo Bianchini",
year = "1998",
doi = "10.1007/s005479900058",
language = "English",
volume = "7",
pages = "28--33",
journal = "International Journal of Angiology",
issn = "1061-1711",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III

AU - Ceriello, Antonio

AU - Sardina, Marco

AU - Motz, Enrico

AU - Lizzio, Sebastiano

AU - Tuniz, Duilio

AU - Bianchini, Carlo

PY - 1998

Y1 - 1998

N2 - Twenty patients, 15 males and 5 females, aged 50-71 years, with peripheral obstructive arterial disease at Fontaine stage III and requiring hospitalization, were randomized to two different iloprost treatment schedules: iloprost i.v. infusion, up to 2 ng/kg/minute for 6 hours/day for 28 days (Group A) or iloprost i.v. infusion, up to 1.5 ng/kg/minute, for 16 hours/day for 7 days (Group B). At baseline, after 7 days (end of treatment, Group B only) and after 28 days (end of study) the following measurements were done: blood pressure and heart rate, ankle/arm pressure index, first flow, peak flow, time to regression (by means of mercury strain-gauge plethysmography), stroke volume, cardiac output, ejection fraction (by means of 2D-echocardiography and echo-Doppler), exercise tolerance (by means of treadmill test), and rest pain (by means of visual analogue scale). Both treatment schedules resulted in significant improvement in plethysmographic parameters and exercise tolerance (both maximal and pain free) with concomitant reduction in rest pain. These effects were long lasting as evident by the results observed in Group: B where the absolute data after 3 weeks of drug withdrawal were superimposable to those of Group A. On the contrary, only mild effects were evident on systemic hemodynamics, which tended to wane off as the infusion was stopped. From the results of this pilot study it is possible to conclude that treatment with iloprost at lower dosage (up to 1.5 ng/kg/minute) for 16 hour/day for 7 days, in patients at Fontaine stage III, seems to result in the same therapeutic benefits of the currently used schedule (up to 2 ng/kg/minute for 6 hour/day for 28 days). If confirmed by larger clinical experience, these data have clear implication in terms of patient comfort and cost containment.

AB - Twenty patients, 15 males and 5 females, aged 50-71 years, with peripheral obstructive arterial disease at Fontaine stage III and requiring hospitalization, were randomized to two different iloprost treatment schedules: iloprost i.v. infusion, up to 2 ng/kg/minute for 6 hours/day for 28 days (Group A) or iloprost i.v. infusion, up to 1.5 ng/kg/minute, for 16 hours/day for 7 days (Group B). At baseline, after 7 days (end of treatment, Group B only) and after 28 days (end of study) the following measurements were done: blood pressure and heart rate, ankle/arm pressure index, first flow, peak flow, time to regression (by means of mercury strain-gauge plethysmography), stroke volume, cardiac output, ejection fraction (by means of 2D-echocardiography and echo-Doppler), exercise tolerance (by means of treadmill test), and rest pain (by means of visual analogue scale). Both treatment schedules resulted in significant improvement in plethysmographic parameters and exercise tolerance (both maximal and pain free) with concomitant reduction in rest pain. These effects were long lasting as evident by the results observed in Group: B where the absolute data after 3 weeks of drug withdrawal were superimposable to those of Group A. On the contrary, only mild effects were evident on systemic hemodynamics, which tended to wane off as the infusion was stopped. From the results of this pilot study it is possible to conclude that treatment with iloprost at lower dosage (up to 1.5 ng/kg/minute) for 16 hour/day for 7 days, in patients at Fontaine stage III, seems to result in the same therapeutic benefits of the currently used schedule (up to 2 ng/kg/minute for 6 hour/day for 28 days). If confirmed by larger clinical experience, these data have clear implication in terms of patient comfort and cost containment.

UR - http://www.scopus.com/inward/record.url?scp=0031973922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031973922&partnerID=8YFLogxK

U2 - 10.1007/s005479900058

DO - 10.1007/s005479900058

M3 - Article

AN - SCOPUS:0031973922

VL - 7

SP - 28

EP - 33

JO - International Journal of Angiology

JF - International Journal of Angiology

SN - 1061-1711

IS - 1

ER -